WO2001000191A3 - Use of fosphenytion for the treatment of acute neuropathic pain - Google Patents

Use of fosphenytion for the treatment of acute neuropathic pain Download PDF

Info

Publication number
WO2001000191A3
WO2001000191A3 PCT/EP2000/006260 EP0006260W WO0100191A3 WO 2001000191 A3 WO2001000191 A3 WO 2001000191A3 EP 0006260 W EP0006260 W EP 0006260W WO 0100191 A3 WO0100191 A3 WO 0100191A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropathic pain
treatment
fosphenytion
acute neuropathic
fosphenytoin
Prior art date
Application number
PCT/EP2000/006260
Other languages
French (fr)
Other versions
WO2001000191A2 (en
Inventor
Gary John Mccleane
Original Assignee
Warner Lambert Co
Gary John Mccleane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Gary John Mccleane filed Critical Warner Lambert Co
Priority to AU58248/00A priority Critical patent/AU5824800A/en
Publication of WO2001000191A2 publication Critical patent/WO2001000191A2/en
Publication of WO2001000191A3 publication Critical patent/WO2001000191A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The invention concerns a method for the treatment of neuropathic pain and particularly acute neuropathic pain. The method comprises administering to a patient in need thereof an effective concentration of fosphenytoin over a prolonged period of time, particularly about 2250 mg (1500 mg PE) of fosphenytoin over a 24 hour period at the rate of about 90 mg (60 mg PE) per hour.
PCT/EP2000/006260 1999-06-23 2000-06-22 Use of fosphenytion for the treatment of acute neuropathic pain WO2001000191A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58248/00A AU5824800A (en) 1999-06-23 2000-06-22 Use of fosphenytoin for the treatment of acute neuropathic pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14064299P 1999-06-23 1999-06-23
US60/140,642 1999-06-23

Publications (2)

Publication Number Publication Date
WO2001000191A2 WO2001000191A2 (en) 2001-01-04
WO2001000191A3 true WO2001000191A3 (en) 2001-05-10

Family

ID=22492170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006260 WO2001000191A2 (en) 1999-06-23 2000-06-22 Use of fosphenytion for the treatment of acute neuropathic pain

Country Status (2)

Country Link
AU (1) AU5824800A (en)
WO (1) WO2001000191A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5781516B2 (en) 2009-09-24 2015-09-24 ウェーブ ガード テクノロジーズ リミテッド Non-ionizing radiation source online radiation management and control system and method
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
US11285099B2 (en) * 2016-12-06 2022-03-29 Topical Innovations B.V. Topical phenytoin for use in the treatment of peripheral neuropathic pain
CN113557018A (en) * 2018-09-14 2021-10-26 国立大学法人富山大学 Therapeutic agent for acute herpes zoster pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925860A (en) * 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925860A (en) * 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHANG V.T.: "Intravenous phenytoin in the management of crescendo pelvic cancer- related pain.", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, (1997) 13/4 (238-240)., XP000986674 *
CHERNY N.I. ET AL: "[Pharmacotherapy of cancer pain. 3. Adjuvant drugs]. MEDIKAMENTOSE THERAPIE VON TUMORSCHMERZEN. TEIL III: ADJUVANZIEN.", SCHMERZ, (1995) 9/2 (55-69)., XP000986851 *
DIENER H.-C. ET AL: "[Therapy and prophylaxis of neuralgias of the face and atypical facial pain. Recommendations of the German Migraine and Headache Society]. THERAPIE UND PROPHYLAXE DER GESICHTSNEURALGIEN UND ANDERER GESICHTSSCHMERZEN. EMPFEHLUNGEN DER DEUTSCHEN MIGRANE- UND KOPFSCHMERZ-GESELLSCHAFT.", NERVENHEILKUNDE, (1994) 13/5 (264-268)., XP000986999 *
KATHLEEN PARFITT: "Martindale - The complete drug reference. Thirty-second edition", 1999, PHARMACEUTICAL PRESS, LONDON, XP002161569, 243700 *
KNAPP L.E. ET AL: "Clinical experience with fosphenytoin in adults: Pharmacokinetics, safety, and efficacy.", JOURNAL OF CHILD NEUROLOGY, (1998) 13/SUPPL. 1 (S15-S18)., XP000987003 *
MACIEWICZ R. ET AL: "Drug therapy of neuropathic pain.", CLINICAL JOURNAL OF PAIN, (1985) 1/1 (39-49). CODEN: CJPAEU, XP000987002 *
MCCLEANE G.J.: "Intravenous infusion of phenytoin relieves neuropathic pain: A randomized, double-blinded, placebo-controlled, crossover study.", ANESTHESIA AND ANALGESIA, (1999) 89/4 (985-988)., XP000986991 *
MCCLEANE, GARY: "Intramuscular fosphenytoin reduces neuropathic pain: A randomized, double-blind, placebo-controlled, crossover study", ANALGESIA (ELMSFORD, N. Y.) (1999), 4(4), 479-482, XP000984196 *

Also Published As

Publication number Publication date
AU5824800A (en) 2001-01-31
WO2001000191A2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
PL341592A1 (en) Method of administering human aspb28 insulin
EP0908186A3 (en) Method for treating pain
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
IL135061A0 (en) Strategic targeted fluoridation and chemical treatment of teeth
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO1999004772A3 (en) Use of levobupivacaine
WO2003100574A3 (en) Dental appliances and systems and methods for distributing dental appliances
WO1999049854A3 (en) Use of dexmedetomidine for icu sedation
AU5739800A (en) Method for direct diagnosis and treatment of pain of muscular origin
GB0020504D0 (en) Therapeutic method
EP0744176A3 (en) Methods for inhibiting bone loss
WO2001000191A3 (en) Use of fosphenytion for the treatment of acute neuropathic pain
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
AU2420101A (en) Method and composition for the treatment of pain
AU2566201A (en) Compounds and methods for the treatment of pain
WO2003059395A3 (en) Antisense compounds directed against human csf-1
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
AU5434899A (en) Cancer treatment
WO2004052331A3 (en) Use of a cotton honeydew extract as active ingredient in or for preparing a cosmetic and/or pharmaceutical composition
AU2001292499A1 (en) 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10- tetrahydropyridazino(4,5-b)quinoline-1,10-dione and the use thereof for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP